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Human immunodeficiency virus type 1 (HIV-1)-associated dementia (HAD) is a severe neurological disease
that affects a subset of HIV-1-infected individuals. Increased compartmentalization has been reported between
blood and cerebrospinal fluid (CSF) HIV-1 populations in subjects with HAD, but it is still not known when
compartmentalization arises during the course of infection. To assess HIV-1 genetic compartmentalization
early during infection, we compared HIV-1 populations in the peripheral blood and CSF in 11 primary
infection subjects, with analysis of longitudinal samples over the first 18 months for a subset of subjects. We
used heteroduplex tracking assays targeting the variable regions of env and single-genome amplification and
sequence analysis of the full-length env gene to identify CSF-compartmentalized variants and to examine viral
genotypes within the compartmentalized populations. For most subjects, HIV-1 populations were equilibrated
between the blood and CSF compartments. However, compartmentalized HIV-1 populations were detected in
the CSF of three primary infection subjects, and longitudinal analysis of one subject revealed that compart-
mentalization during primary HIV-1 infection was resolved. Clonal amplification of specific HIV-1 variants was
identified in the CSF population of one primary infection subject. Our data show that compartmentalization
can occur in the central nervous system (CNS) of subjects in primary HIV-1 infection in part through
persistence of the putative transmitted parental variant or via viral genetic adaptation to the CNS environ-
ment. The presence of distinct HIV-1 populations in the CSF indicates that independent HIV-1 replication can
occur in the CNS, even early after HIV-1 transmission.
Human immunodeficiency virus type 1 (HIV-1) infection of
the central nervous system (CNS) can lead to neurological
disease in a subset of HIV-infected individuals and may in-
clude the development of HIV-1-associated dementia (HAD)
(2, 18). HAD is characterized by severe neurological dysfunc-
tion, and affected individuals generally have impaired cognitive
and motor functions. HIV-1 enters the CNS during primary
infection, most likely via the migration of infected monocytes
and lymphocytes across the blood-brain barrier (33, 37, 42).
The main cell types in the CNS that HIV-1 can productively
infect are the perivascular macrophages and microglial cells,
which express low receptor densities of CD4, CCR5, and
CXCR4 (7, 18, 60, 63). Previous studies have also reported that
neurotropic HIV-1 variants are generally macrophage tropic
(19, 20, 32, 45, 52, 61). Although cells in the CNS may be
infected with HIV-1 during the course of disease, it is still
unclear whether productive HIV-1 replication occurs in the
CNS early during infection.
Genetically compartmentalized HIV-1 variants have been
detected in the brains of HAD subjects at autopsy (13, 14, 43,
48, 52) and in the cerebrospinal fluid (CSF) of HAD subjects
sampled over the course of infection (26, 46, 51, 59). Extensive
compartmentalization between the periphery and the CNS has
been reported in subjects with HAD; however, it is not yet
known when compartmentalization occurs during the course of
HIV-1 infection. Primary HIV-1 infection refers to the acute
and early phases of infection, during which peak plasma vire-
mia often occurs and a viral “set point” may be reached (8, 34),
within the first year after HIV exposure (64). Studies examin-
ing compartmentalization between the blood plasma and CSF
during primary infection have been limited, and extensive com-
partmentalization has not been detected in primary infection
subjects (26, 50).
In this study, we examined HIV-1 genetic compartmentaliza-
tion between the peripheral blood and CSF during primary
HIV-1 infection. Cross-sectional and longitudinal blood plasma
and CSF samples were analyzed for viral compartmentalization
using the heteroduplex tracking assay (HTA) and single genome
amplification (SGA). We used the HTA to differentiate be-
tween HIV-1 variants in the CSF that were either compart-
mentalized to the CSF or equilibrated with the peripheral
blood. Previous studies have used the HTA to separate HIV-1
genetic variants in different anatomical compartments (10, 24,
27, 51) and to follow HIV-1 evolutionary variants over the
course of infection (9, 25, 31, 41, 49, 50). We also conducted
SGA on a subset of subjects to further examine viral genetic
compartmentalization during primary infection. Here we re-
port the detection of compartmentalized and clonally ampli-
fied HIV-1 variants in the CSF of subjects in the primary stage
of HIV-1 infection. Our results suggest that minor to extensive
HIV-1 genetic compartmentalization can occur between the
periphery and the CNS during primary HIV-1 infection and
that viral compartmentalization, as measured in the CSF, is
transient in some subjects.
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MATERIALS AND METHODS
Subject population. The study subjects were individuals enrolled in a neuro-
logical study of acute and early HIV-1 infection at the University of California at
San Francisco. Diagnosis of primary HIV-1 infection at enrollment followed the
previously described Serologic Testing Algorithm for Recent HIV Seroconver-
sion (STARHS) (40). In brief, subjects had positive HIV-1 nucleic acid tests and
either had negative antibody tests in the past 12 months or had a less sensitive
enzyme immunoassay (EIA) result supportive of infection within the previous 6
months. Further estimation of the number of days since HIV-1 exposure (days
postinfection [p.i.]) was based upon the presence of symptoms of an acute
seroconversion reaction or taken as the halfway point between the last negative
and first positive antibody tests (35, 36). Serial blood plasma and cerebrospinal
fluid samples were collected for study purposes as early as possible after initial
diagnosis and at various intervals thereafter. Plasma and CSF HIV-1 RNA
concentrations were determined using the Amplicor HIV Monitor kit (Roche).
The study was approved by the Committee for Human Research at the Univer-
sity of California at San Francisco, and all subjects provided written informed
consent for the collection of samples.
Markers of inflammation. Entry blood and CSF determinations, including cell
counts, protein, and albumin, were performed by the San Francisco General
Hospital Clinical Laboratories. CSF neopterin was assayed using a commercially
available enzyme-linked immunosorbent assay (ELISA) according to the ven-
dor’s methods (Henning Berlin GMBH, Berlin, Germany).
Viral RNA isolation, RT-PCR, HTA, and PhosphorImager analysis. Proce-
dures for viral RNA isolation, RT-PCR, and HTA have been previously de-
scribed (11, 12, 24, 31, 41, 49). HIV-1 RNA was isolated from blood plasma and
CSF samples (140 l), using a QIAmp viral RNA kit (Qiagen). All CSF samples
were centrifuged at 1,000  g for 5 min prior to RNA isolation to remove
contaminating cellular debris. To increase template number, samples with viral
RNA levels less than 10,000 copies/ml were pelleted (0.5 to 1.0 ml) by centrif-
ugation at 25,000  g for 1.5 h prior to RNA isolation. Reverse transcription and
PCR amplification of the V1/V2 and V4/V5 regions of env were conducted with





b CD4c CSF WBCd Plasma HIVRNAe
CSF HIV
RNAe Albumin ratio
f CSF neoptering % Differenceh
9003 3/1/06 78 1044 2 26,400 49 3.38 7.3
9010 10/10/06 235 497 11 1,030 206 5.55 9.5
9012 2/8/07 103 601 8 74,131 398 11.09 14.3
9014 3/20/07 169 751 12 35,481 537 4.13 8.5
9016 4/24/07 143 353 1 776,247 49 5.44 6.6
9017 6/20/07 49 361 14 17,378 151 4.51 8.6
9001 12/14/05 206 488 3 153,000 246 4.55 14.3 NR
3/22/06 305 573 4 194,000 1,180 3.50 19.0 19.0
6/21/06 393 575 5 74,800 4,120 4.33 20.5 10.4
9002 2/15/06 86 770 6 7,670 19 6.47 8.9 0
4/6/06 137 686 2 16,500 208 6.69 11.3 0
8/22/06 273 539 8 44,800 4,560 7.35 21.0 0
9/26/06 306 542 14 32,400 4,630 9.29 21.3 0
10/26/06 336 501 14 37,200 12,000 9.61 17.0 0
12/14/06 384 640 12 198,000 8,130 9.67 15.1 0
5/8/07 528 546 11 13,800 1,280 9.79 9.0 0
7/17/07 597 459 2 40,000 515 8.73 10.1 6.6
9006 9/14/06 150 435 8 27,700 1,300 4.64 12.9 0
11/1/06 197 512 6 29,000 1,310 4.31 NA 0
3/20/07 336 453 6 65,600 1,620 3.75 NA 15.9
9007 9/18/06 149 256 4 233,000 426 10.85 33.1 NR
11/2/06 193 336 9 183,000 3,250 7.88 23.5 14.4
6/5/07 406 292 4 29,500 3,900 6.87 22.9 7.4
9019 8/13/07 58 750 13 49,300 1,390 5.58 13.9 2.2
9025 4/21/08 50 752 7 101,000 15,200 3.91 NA NA
9037 5/14/09 46 884 26 507,652 2,682 6.35 NA NA
9039 6/1/09 36 539 53 367,728 19,911 9.31 NA NA
9018 8/2/07 198 350 11 404,000 37,500 6.45 11.6 29.2
9040 6/15/09 165 705 4 16,710 6,176 7.67 NA NA
7146 9/23/03 156 552 86 429,000 168,000 14.35 56.6 23.9
10/14/03 177 476 97 217,000 24,900 14.35 41.2 19.1
11/10/03 203 310 53 103,000 26,000 7.12 23.5 41.1
4/29/04 372 380 1 13,399 19 4.39 14.5 NA
6/24/04 427 337 2 225,000 36 7.31 NA NA
10/7/04 530 305 2 308,000 2,630 5.40 20.0 15.9
a ID, identifier. Antibody (Ab) data were as follows: subject 9003, 1 band (p24) on 12/20/05; subject 9010, negative Ab on 8/2005; subject 9012, not known; subject
9014, negative Ab on 8/4/06, positive Ab on 12/6/07; subject 9016, positive HIV RNA, negative Ab on 12/27/06; subject 9017, not known; subject 9001, negative Ab on
5/25/05, 10 bands on 11/1/05; subject 9002, 10 bands on 1/3/06; subject 9006, 2 bands (p24 and gp160) on 5/5/06; subject 9007, not known; subject 9019, positive HIV
RNA, negative Ab on 6/2007; subject 9025, negative HIV RNA on 1/14/08, HIV RNA 10,000 cps/ml and negative Oraquick on 3/13/08, and positive Ab on 3/20/08;
subject 9037, negative EIA with positive ELISA on 4/19/09; subject 9039, not known; subject 9018, last negative Ab on 11/4/06; subject 9040, negative Ab on 11/4/08,





f CSF/plasma albumin ratio.
g Nanomoles per liter; NA, not applicable.
h Percent differences between plasma and CSF viral populations as measured by HTA. The reported values are the averages calculated from two independent HTA
replicates (see references 31 and 49 for the methods). Percent differences were not measured for subjects 9003, 9010, 9012, 9014, 9016, and 9017 due to low CSF HIV-1
RNA levels. NR, not reported due to poor sampling.
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5 l of purified RNA (from a 60-l-column elution volume), using a Qiagen
one-step RT-PCR kit per the manufacturer’s instructions and using previously
described primers for V1/V2 (31, 49) and V4/V5 (49).
The heteroduplex annealing reactions have been previously described (31, 41).
Heteroduplexes were separated by 6% native polyacrylamide gel electrophoresis
for V1/V2 and V4/V5 HTA (24, 31). The HTA probes used in these studies
included the V1/V2 Ba-L probe (31, 49), the V1/V2 JRFL probe (31, 49), the
V4/V5 NL4-3 probe (24), and the V4/V5 YU2 probe (49). The HTA gels were
dried under vacuum, and bands were visualized by autoradiography. The dried
HTA gels were exposed to a PhosphorImager screen, and the relative abundance
of each detected viral variant (heteroduplex) was calculated using ImageQuant
software (Molecular Dynamics). The variant RNA concentration was calculated
by multiplying the relative abundance of each individual variant by the total
HIV-1 RNA concentration for that sample. Template sampling was validated by
analyzing duplicate RT-PCR products by HTA for each sample. For any time
point where the HTA patterns differed significantly between the two replicates
(20%), the samples were not used in data analysis. Percent difference values
between plasma and CSF viral populations were calculated as previously de-
scribed (31, 49).
Single-genome amplification. HIV-1 RNA was isolated as described above.
Viral RNA was reverse transcribed using Superscript III reverse transcriptase
(Invitrogen) and oligo(dT) according to the manufacturer’s instructions. SGA of
the full-length HIV-1 env gene through the 3 U3 region was conducted as
previously described (29, 44, 53). Briefly, cDNA was endpoint diluted, and nested
PCR (15, 56) was conducted using Platinum Taq High Fidelity polymerase
(Invitrogen) as described by Salazar-Gonzalez et al. (53). The primers B5853
UP0 (5-TAGAGCCCTGGAAGCATCCAGGAAG-3) and LTR DN1 (5-GA
CTCTCGAGAAGCACTCAAGGCAAGCTTTATTGAG-3) were used for the
first round of PCR. The primers B5957 UP1 (5-GATCAAGCTTTAGGCATC
TCCTATGGCAGGAAGAAG-3) and LTR DN1 were used for the second
round of PCR. The SGA amplicons were then sequenced from the start of V1
through the ectodomain of gp41 (HIV HXB2 numbering of positions 6600 to
8000).
Phylogenetic and compartmentalization analyses. The nucleotide sequences
of the env genes were aligned using Clustal W (4, 62) or MAFFT software (28).
Maximum likelihood phylogenetic trees were generated using PhyML (22) with
the following parameters: HKY85 nucleotide substitution model, four substitu-
tion rate categories, estimation of the transition/transversion rate ratio, estima-
tion of the proportion of invariant sites, and estimation of the gamma distribu-
tion parameter (21). All sequences were subjected to quality control analysis to
ensure that sequences from different subjects were not mislabeled.
Variants in the CSF were considered compartmentalized by the HTA if they
were unique to the CSF or if they had a substantially higher copy number in the
CSF than in the plasma. Compartmentalization of CSF viral populations by
sequence was determined using the Slatkin-Maddison test for compartmental-
ization (57) implemented in the HyPhy software (47) and using 10,000 permu-
tations.
Nucleotide sequence accession numbers. The nucleotide sequences deter-
mined in this study have been deposited in GenBank under accession numbers
GQ49667 to GQ497076 and GU206564 to GU206786.
RESULTS
Study population characteristics and inflammatory mark-
ers. Our study included 17 subjects enrolled in a neurological
primary HIV-1 infection cohort for which we attempted to
examine CNS compartmentalization during primary infec-
tion (Table 1 lists the clinical and laboratory characteris-
tics). Eleven subjects had sufficient viral-RNA loads in both
the plasma and CSF compartments for HTA and SGA analyses
of the viral populations. All subjects in this study had higher
HIV-1 RNA concentrations in the plasma than in the CSF, and
a substantial proportion (35%; 6 of 17) of the subjects had
FIG. 1. Cross-sectional and longitudinal HTA analysis of HIV-1 in the blood plasma and CSF of primary infection subjects. (A) Longitudinal
V1/V2 or V4/V5 HTA analysis of HIV-1 using paired blood plasma and CSF samples from 5 subjects without compartmentalized CSF variants.
The HTA shown for subject 9007 targeted the V1/V2 region of env, and the V4/V5 HTA is shown for all other subjects. Sample time points are
listed above each HTA gel as days p.i. The HTA gel images for the CSF viral population of subject 9001 at 206 days p.i. and subject 9007 at 149
days p.i. are not included because there was poor reproducibility between the HTA replicates due to low CSF viral loads. (B) Longitudinal V4/V5
HTA analysis of HIV-1 using paired blood and CSF samples from 2 subjects with compartmentalized CSF variants. CSF-compartmentalized
variants are indicated by filled black circles next to the gel images. A variant enriched in the CSF is indicated with a filled black square next to the
gel image.
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extremely low CSF HIV-1 RNA concentrations at study entry
(mean  232  197 copies/ml), in contrast to the other 11
subjects (mean  22,986  49,492 copies/ml). Viral population
characteristics were not analyzed for six subjects with low CSF
viral loads at entry (subjects 9003, 9010, 9012, 9014, 9016, and
9017).
We measured inflammation and cell migration into the CNS
for each subject through several indirect analyses, including
CSF/plasma albumin ratios, CSF white blood cell (WBC)
counts, and CSF neopterin levels. The CSF/plasma albumin
ratios were calculated as a measure of blood-brain barrier
(BBB) disruption, while CSF WBC levels were measured as a
simple marker of inflammation and inflammatory-cell migra-
tion into the CNS. Additionally, the level of CSF neopterin, a
pteridine produced by activated macrophages and associated
with intrathecal immunoactivation, is elevated in HIV-infected
subjects and is characteristically particularly high (22 nmol/
liter) in those with HIV-1-associated dementia (3, 17). All 17
subjects were enrolled within the first year of infection, with a
median at baseline of 143 days p.i. (interquartile range, 58 to
165 days). The subjects were naïve to antiretroviral treatment
at enrollment, and only one subject started treatment during
the study intervals reported here (subject 7146, after 10 No-
vember 2003).
Based on the published normal values of CSF WBC (0 to 5
cells/l) (16) and the CSF/albumin ratio (6.8) (1), most subjects
had mild to moderate CNS inflammation and blood-brain barrier
disruption during this early stage of infection. Subject 7146 was
FIG. 2. Phylogenetic analysis of plasma and CSF HIV-1 populations. (A) Phylogenetic trees of HIV-1 env sequences for subjects 9002,
9025, 9037, and 9039, which display equilibration between blood plasma and CSF HIV-1 populations. (B) Phylogenetic trees of HIV-1 env
sequences for subject 9007 at 149 days p.i. (dpi) and 406 days p.i. HIV-1 populations were equilibrated at 149 days p.i. but became slightly
discordant at 406 days p.i. (C) Phylogenetic tree of HIV-1 env sequences for subject 9040, which displays significant compartmentalization
in the CSF. The open blue circle indicates the node of divergence for the compartmentalized CSF sequences. SGA amplicons were first
aligned, and a maximum likelihood phylogenetic tree was constructed using PhyML. Bootstrap numbers 70 are indicated at the appropriate
nodes. Sequences obtained from the CSF are labeled with solid blue circles, and plasma sequences are labeled with solid red rectangles on
the tree. The genetic distances between sequences are indicated by the distance scale bars at the bottoms of the trees.
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symptomatic at the time of enrollment, with clinical meningitis
that was presumed to be secondary to HIV-1 seroconversion
(extensive laboratory evaluations for standard bacteria, tu-
berculosis, spirochetes, and fungal organisms were negative),
and had the highest CSF WBC level, CSF/plasma albumin
ratio, and CSF neopterin level in the group (Table 1). All other
subjects for whom HTA or SGA was performed were neuro-
logically asymptomatic at study enrollment.
Compartmentalization of HIV-1 variants in the CSF during
primary infection. The HTA is a useful tool for resolving and
quantifying complex viral populations based on genotype and
is able to detect minor variants within the viral population. We
utilized HTAs targeting the hypervariable regions V1/V2 and
V4/V5 of the env gene to detect and distinguish between com-
partmentalized and noncompartmentalized HIV-1 variants in
the CSF and plasma of primary infection subjects. Cross-sec-
tional HTA analyses were conducted on 7 primary infection
subjects, and we were able to classify the relationship between
the blood and CSF viral populations into two groups. Five
subjects (9001, 9002, 9006, 9007, and 9019) (Fig. 1A) showed
concordance (the difference between blood and CSF was
20%) between the blood plasma and CSF viral populations
at the earliest time point sampled.
The second group (subjects 9018 and 7146) had evidence of
compartmentalization when the blood and CSF viral popula-
tions at study entry were compared (Fig. 1B). In this small
study, the two subjects with compartmentalized variants in the
CSF had higher CSF viral loads than subjects with concordant
populations in the plasma and CSF (Table 1). HIV-1 popula-
tions in the plasma and CSF were also discordant in subjects
with CSF-compartmentalized variants as measured by percent
difference (9018, 29.2% different at 198 days p.i.; 7146, 23.9%
different at 156 days p.i.). In this group, subject 9018 had only
mild CNS inflammation, while subject 7146 had evidence of
significant inflammation in the CNS (Table 1). These results
show that HIV-1 compartmentalization in the CSF can occur
during primary infection and as early as 5 months after HIV-1
transmission.
Compartmentalization during primary HIV-1 infection can
be transient. Longitudinal HTA analyses were conducted to
examine compartmentalization in the CSF over the course of
primary HIV-1 infection (subjects 9001, 9002, 9006, 9007, and
7146). HIV-1 populations in the plasma and CSF were con-
cordant over time for subjects 9001, 9002, 9006, and 9007, with
some minor variations (Table 1 lists percent differences). In
subject 9001, viral populations in the plasma and CSF were
concordant at each time point; however, the viral population
underwent substantial divergence between time points, dem-
onstrating equilibration between these compartments even as
the virus was evolving in the periphery. Conversely, HTA anal-
ysis of subject 9002 revealed concordance between the plasma
and CSF populations over time, with only a small amount of
viral diversification detected at 597 days p.i. The results for
subjects 9006 and 9007 are summarized in Fig. 1 and Table 1.
We conclude that for these subjects most of the virus detected
in the CSF was recently imported from the periphery and
underwent little independent replication in the CNS.
Longitudinal HTA analysis of subject 7146 revealed one
viral variant that was compartmentalized in the CSF at 156 and
177 days p.i., although by 177 days p.i. this variant comprised a
small minority of the total CSF viral population. We also no-
ticed that a new viral variant was significantly enriched in the
CSF viral population at day 203 postinfection (Fig. 1B). How-
ever, the plasma and CSF viral populations had equilibrated
again by 530 days p.i. At that time point, the CSF variant that
was enriched at 203 days p.i. still seemed to be slightly enriched
in the CSF compared to the plasma population, although the
difference was minor. These results indicate that when com-
partmentalization occurs during primary HIV-1 infection, it
can be transient, and the CSF viral population can change
substantially over the course of primary HIV-1 infection.
Single genome amplification confirms compartmentaliza-
tion and identifies clonal amplification of HIV-1 variants in
the CSF of primary infection subjects. We examined the ge-
netically compartmentalized viral variants in more detail by
conducting SGA on plasma and CSF samples from subjects
with detectable compartmentalization in the CSF by HTA
(subjects 9018 and 7146). We also conducted SGA for two
subjects (9002 and 9007) with HIV-1 populations equilibrated
between the plasma and CSF and on 4 additional subjects who
were not analyzed by the HTA (9025, 9037, 9039, and 9040)
(Fig. 2 and Table 2). The structure of the phylogenetic trees
and limited env sequence diversity suggest that subjects 9002,
9007, 9025, 9037, and 9039 were each infected with a single
HIV-1 variant during transmission. We found that the plasma
and CSF env sequences for subjects 9002, 9025, 9037, and 9039
mixed together throughout their respective phylogenetic trees,
indicating that the two compartments were well equilibrated
for each subject (Fig. 2A). In addition, the CSF env sequences
for these subjects were not considered compartmentalized us-
ing the Slatkin-Maddison test (9002, P  0.56; 9025, P  0.84;
9037, P  0.057; 9039, P  0.97). Subject 9007 had plasma and
CSF HIV-1 populations that were well equilibrated at 149 days
p.i. (Slatkin-Maddison test; P  0.6928), although the viral
populations were somewhat discordant 406 days p.i. (Fig. 2B)
(Slatkin-Maddison test; P  0.0397). These data confirm the
HTA analysis showing that the plasma and CSF can be fully
equilibrated.
SGA was also conducted on the cross-sectional plasma and
CSF samples for subject 9018, which had one compartmental-













9002 10/26/06 338 20 26 Eq
9007 9/18/06 149 29 15 Eq
6/5/07 406 20 28 Uneq
9018 8/2/07 198 29 22 Comp
9025 4/21/08 50 19 27 Eq
9037 5/14/09 46 37 29 Eq
9039 6/1/09 36 40 24 Eq
9040 6/15/09 165 23 24 Comp
7146 9/23/03 156 22 27 Comp, Amp
10/14/03 177 36 29 Eq
11/10/03 203 26 26 Comp, Amp
10/7/04 530 33 22 Eq
a Estimated.
b HIV-1 population characteristics in the CSF compartment. Eq, equilibration
with the blood plasma; Unequ, discordance between the CSF and blood plasma
without substantial compartmentalization; Comp, compartmentalization in the
CSF; Amp, clonal amplification of variants detected in the CSF.
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FIG. 3. Phylogenetic and sequence analyses of plasma and CSF HIV-1 populations at 198 days p.i. for subject 9018. (A) Maximum likelihood
phylogenetic tree. Sequences from the CSF (C) are labeled with solid blue circles, and plasma sequences (P) are labeled with solid red rectangles.
Genetic distances between sequences are indicated by the scale bars located at the bottom of the tree. Bootstrap values of 50 are labeled at the
appropriate nodes. Putative transmitted viruses are labeled with asterisks, and CSF populations that were considered compartmentalized based on
the phylogenetic analysis are indicated with a solid black line. (B) Highlighter plot of aligned env plasma and CSF sequences. The HXB2 base
number is indicated on the x axis, and the sequence identifier is indicated on the y axis. Base changes are indicated by the following ticks on the
highlighter plot: A, green; T, red; G, orange; C, light blue; and gaps, gray.
2400
FIG. 4. Phylogenetic and sequence analyses of subject 7146 HIV-1 populations in the plasma and CSF at 156 days p.i. (A) Maximum likelihood
phylogenetic tree. Sequences from the CSF (C) are labeled with solid blue circles, and plasma sequences (P) are labeled with solid red rectangles.
Bootstrap values of 50 are labeled at the appropriate nodes. Genetic distances between sequences are indicated by the scale bar located at the
bottom of the tree. The clonally amplified HIV-1 variants in the CSF population are indicated by the black bracket. Putative transmitted viruses
are labeled with asterisks, and CSF populations that were compartmentalized are indicated with solid black lines. (B) Highlighter plot of aligned
plasma and CSF env sequences. The HXB2 base number is indicated on the x axis, and the sequence identifier is indicated on the y axis. Base
changes are indicated by the following ticks on the highlighter plot: A, green; T, red; G, orange; C, light blue; and gaps, gray.
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ized variant detected by HTA, and subject 9040. We detected
significant compartmentalization between the blood plasma
and CSF HIV-1 populations for subject 9040 (Fig. 2C) (Slat-
kin-Maddison test; P  0.0001), and further sequence analysis
demonstrated that all of the compartmentalized variants en-
coded a common V169R amino acid substitution in the V1/V2
stem region of the Env protein. Similarly, phylogenetic analysis
of subject 9018 revealed a subset of env sequences derived
from the CSF that branched separately from the rest of the
sequences in the tree (Fig. 3A). In addition, the compartmen-
talized population in the CSF had a unique Q170R amino acid
substitution in the V1/V2 stem of the envelope. However, the
CSF viral population was not considered compartmentalized
by the Slatkin-Maddison test (P  0.1078). Even though the
entire CSF viral population was not considered compartmen-
talized, a small HIV-1 population in the CSF appeared to be
compartmentalized based on the phylogenetic tree structure
and good bootstrap support for this node (Fig. 3A).
Based on the sequence and phylogenetic data, subject 9018
was likely infected with at least two viral variants during trans-
mission. The two sequences that are likely closest to the pa-
rental viruses are 9018 C 13/9018 P 1 and 9018 C 14 (Fig. 3B),
and recombination between the transmitted viruses appears to
account for much of the env genetic diversity detected in both
the plasma and CSF populations. This interpretation also leads
to the conclusion that one of the putative transmitted se-
quences was underrepresented in the periphery and main-
tained in the CNS.
Longitudinal SGA analysis of subject 7146 revealed tran-
sient compartmentalization and clonal amplification in the
CSF HIV-1 population. Based on the phylogenetic tree struc-
ture and env sequence diversity at the first time point sampled
(156 days p.i.), we believe that subject 7146 was infected with
two HIV-1 variants during the transmission event (Fig. 4A).
The viral variants that appear to be most closely related to the
parental viruses are 7146 1P 1 and 7146 1C 1 (Fig. 4B), and
extensive recombination between the two transmitted viruses
can account for most of the variants. Similar to what we de-
tected in the phylogenetic analysis of subject 9018, one of the
transmitted variants was maintained in the CSF but largely
absent from the plasma viral population.
Phylogenetic analysis of the first time point for subject 7146
(156 days p.i.) revealed compartmentalization between the
plasma and CSF viral populations (Fig. 4A), and this was
associated with increased inflammation in the CNS (Table 1).
In particular, one HIV-1 variant was clonally amplified in the
CSF population (Fig. 4A, bracket). Compartmentalization was
confirmed using the Slatkin-Maddison test (P  0.0047), and
the CSF population was still considered compartmentalized
when the clonally amplified viral variants were removed from
the analysis (P  0.0437). The plasma and CSF populations in
subject 7146 were equilibrated by 177 days p.i. (Fig. 5A) (Slat-
kin-Maddison test; P  0.2964), coincident with elevated mea-
sures of BBB disruption (Table 1). The CSF viral population
was considered compartmentalized again at 203 days p.i. based
on phylogenetic analysis (Fig. 5B) (Slatkin-Maddison test; P 
0.0048) and in the setting of a reduced CSF/plasma albumin
ratio. We also detected a small cluster of clonally amplified
sequences in the CSF-compartmentalized population at 203
days p.i., although the viral populations were equilibrated
again by 530 days p.i. (data not shown) (Slatkin-Maddison test;
P  0.877).
A phylogenetic tree containing representative data from all
four time points sampled for subject 7146 revealed that the
clonally amplified variants in the CSF at 156 days p.i. had died
out of the CSF population by 177 days p.i. and did not give rise
to any additional CSF viral variants (Fig. 6, bracket). In addi-
tion, HIV-1 variants in the CSF that were compartmentalized
at 203 days p.i. (Fig. 6, arrows) arose from one main branch in
the phylogenetic tree, and these variants were lost by 530 days
p.i.. Clonally amplified variants detected in the CSF at 203 days
p.i. were also lost from the viral population by 530 days p.i. We
noticed that CSF sequences compartmentalized at 203 days p.i.
branched with sequences detected in the CSF at 156 and 177
days p.i., even though no compartmentalized variants were
detected in the CSF at 177 days p.i. This indicates that CSF
variants detected at entry were maintained over the course of
several months in the CNS of this subject. These data suggest
that compartmentalization during primary infection can be
resolved and recur later during infection. Additionally, tran-
sient clonal amplification can occur in the CSF-compartmen-
talized viral population.
DISCUSSION
Extensive HIV-1 genetic compartmentalization between the
periphery and the CNS has been reported in subjects with
HAD (13, 14, 26, 43, 46, 48, 51, 52, 59). Compartmentalized
viral variants present in the CSF of HAD subjects are thought
to originate from long-lived cells in the CNS (54) and are
maintained in the population by independent viral replication
in the brain. The time at which compartmentalization occurs
during the course of HIV-1 infection has been a subject of
debate, and the absence of CSF-compartmentalized variants
during primary infection has supported the idea that compart-
mentalization occurs later during chronic infection (26, 51).
The goal of our current work was to determine whether com-
partmentalized HIV-1 variants are present in the CSF of pri-
mary infection subjects and to examine the evolution of CSF
variants over the course of early HIV-1 infection.
In this study, we used heteroduplex tracking assays (HTAs)
and single-genome amplification (SGA) to identify CSF-com-
partmentalized variants and to examine the compartmental-
ized viral populations. Cross-sectional HTA analysis revealed
FIG. 5. Phylogenetic analysis of subject 7146 HIV-1 populations at days 177 and 203 postinfection. (A) Phylogenetic tree of plasma and CSF HIV-1
env sequences at 177 days p.i. (B) Phylogenetic tree of HIV-1 populations at 203 days p.i. Sequences from the CSF (C) are labeled with solid blue circles,
and plasma sequences (P) are labeled with solid red rectangles. The CSF sequences that were considered compartmentalized are indicated by the solid
black lines. Clonally amplified HIV-1 variants in the CSF population are indicated by the black bracket. Bootstrap values of 50 are labeled at the
appropriate nodes. Genetic distances between sequences are indicated by the scale bars located at the bottoms of the trees.
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several examples of compartmentalized HIV-1 variants in the
CSF early during HIV-1 infection. We also observed that com-
partmentalization during primary HIV-1 infection could be
transient, and the compartmentalized variants in the CSF
changed over time. Our SGA analyses confirmed the detection
of compartmentalized variants in the CSF and identified clonal
amplification of CSF variants in one subject with primary in-
fection (subject 7146).
A proportion of the primary infection subjects enrolled in
our study had low baseline CSF viral loads, even though the
plasma viral loads were high. One explanation is that plasma
virus is not efficiently entering the CNS in these subjects, while
another possibility is that HIV-1 that enters the CSF/CNS is
being rapidly cleared. In either case, our data suggest that
substantial autonomous viral replication is not occurring in the
CNS of this subset of primary infection subjects. This is con-
sistent with our finding that the majority of primary infection
subjects in our study had concordant viral populations between
the plasma and CSF compartments. The detection of equili-
brated viral populations in the CSF early during HIV-1 infec-
tion indicates that the CSF compartment is accessible to most
of the peripheral HIV-1 variants and supports an absence of
sustained viral replication in the CNS, although independent
viral replication in the CNS may be occurring at a level below
our limit of detection.
Three of the primary infection subjects that we analyzed had
compartmentalized HIV-1 variants present in their CSF viral
populations, indicating that local viral replication can occur in
the CNS at this stage. Subjects 9018 and 7146 had a multiple-
variant transmission event based on our sequence and phylo-
genetic data, where one HIV-1 lineage was detected in both
the plasma and CSF while a second transmitted virus lineage
was detected only in the CSF virus population (Fig. 3 and 4).
These data suggest that some CSF variants have properties
that permit enhanced replication in the CNS, even early after
viral transmission.
Phylogenetic and sequence analysis of subject 9040 revealed
a V169R single-amino-acid substitution in the V1/V2 stem
region of Env for CSF variants that were compartmentalized,
and this change was not detected in any of the plasma env
sequences. The compartmentalized HIV-1 variants in the CSF
of subject 9018 had a Q170R substitution similar to a basic
amino acid in the same region of the Env protein, and HIV-1
variants in the plasma and CSF of 7146 had an R/K170 geno-
type. This suggests that perhaps basic amino acid substitutions
in the V1/V2 stem of Env enhance viral replication in the CNS
FIG. 6. Longitudinal phylogenetic analysis of subject 7146 HIV-1
populations. Shown is a phylogenetic tree of a representative set of
plasma and CSF HIV-1 env sequences from 156 days p.i. (1P, light-
pink square; 1C, light-blue circle), 177 days p.i. (2P, dark-pink square;
2C, bright-blue circle with dark outline), 203 days p.i. (3P, bright-red
square; 3C, royal blue circle), and 530 days p.i. (4P, dark-red-brown
square; 4C, navy blue circle). CSF sequences that were clonally am-
plified at 156 days p.i. are indicated by the black bracket, and CSF
sequences that were considered compartmentalized at 203 days p.i. are
indicated with arrows. Bootstrap values of 50 are labeled at the
appropriate nodes. Genetic distances between sequences are indicated
by the scale bar located at the bottom of the tree.
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environment. One possibility is that additional basic amino
acids in the V1/V2 stem could enhance the binding and entry
of these viral variants into cells with low receptor densities on
the surface, such as perivascular macrophages and microglia in
the CNS. However, basic amino acid substitutions in the V1/V2
stem do not completely explain compartmentalization during
primary infection, since several subjects without compartmen-
talized variants in the CSF had additional basic amino acid
substitutions within their plasma and CSF HIV-1 populations
(data not shown).
Studies examining viral populations in the CSF of primary
HIV-1 infection subjects have been limited; however, a small
study by Harrington et al. (23) examined the population dy-
namics of simian immunodeficiency virus SIVsm strain E660 in
the blood and CSF of macaques over the course of infection. A
comparison of the blood and CSF viral populations revealed
two distinct patterns of evolution: viral genetic concordance
between the blood and CSF populations in two macaques and
discordance in the blood/CSF populations in a third macaque
(23). Notably, the blood/CSF population discordance that was
detected in animal C002 arose early after transmission (day 27)
and persisted over the course of infection (23). Similarly, we
detected concordance between the blood plasma and CSF viral
populations for eight of the primary infection subjects in our
study. Three subjects in our study showed discordance and
compartmentalization in the CSF viral population, and this
disturbance was apparent early after transmission (5 months).
Additionally, Harrington et al. (23) reported increased levels
of CSF monocyte chemoattractant protein 1 (MCP-1) and
statistically significant numbers of infiltrating CD68 macro-
phages in brain sections of macaque C002 compared to other
animals in the study (23). Human studies have also shown that
the levels of chemokines, such as gamma interferon-inducible
protein 10 (IP-10) and MCP-1, are elevated in the CSF of
HAD subjects compared to asymptomatic subjects (5, 6, 30,
55). Although our measures of CNS inflammation differ from
those in the macaque study, we detected elevated levels of CSF
neopterin and pleocytosis in one subject with moderate CSF
compartmentalization.
One easily measured marker of inflammation in the CNS is
pleocytosis, defined as CSF WBC counts  5 cells/l (38, 58).
Although pleocytosis can occur at any stage of neurological
disease, during chronic infection, increased CSF WBC counts
are correlated with CSF HIV-1 RNA concentrations (39, 58).
Subject 7146 had elevations in CSF WBC, as well as CSF
neopterin and the albumin ratio, prior to initiation of antiret-
roviral therapy (Table 1). We believe this inflammatory envi-
ronment in the CNS resulted from both independent HIV-1
replication and the correlated meningitis detected at entry in
subject 7146. The detection of BBB disruption also suggests an
increased ability of lymphocytes to traverse the BBB and move
into the CNS. Subjects 9018 and 9040 also had evidence of
compartmentalization of CSF variants; however, CSF WBC
counts, CSF neopterin levels, and albumin ratios were not
distinct from those in subjects without compartmentalization.
Thus, marked inflammation at a given time point is not nec-
essary for the production or maintenance of compartmental-
ized variants.
One specific viral lineage in subject 7146 was clonally am-
plified in the CSF viral population at 156 days p.i., and our
longitudinal SGA analysis determined that this viral lineage
died out in both the CSF and plasma populations by 177 days
p.i. We believe that an influx of inflammatory cells may have
resulted in the clonal amplification of specific CSF viral vari-
ants at entry. Monocytes and CD4 T cells migrating into the
CNS would provide a larger target cell population for HIV-1
infection and might stimulate increased HIV-1 replication in
the CNS. A small population of clonally amplified variants was
also detected in the CSF at 203 days p.i., when CSF pleocytosis
was still apparent. These data suggest that independent HIV-1
replication may occur in the CNS of primary infection subjects
with detectable compartmentalized variants, and this viral rep-
lication may cause increased inflammation in the CNS that can
result in the clonal expansion of CSF variants.
In conclusion, our study illustrates a complex pattern of
HIV-1 evolution in the CNS during primary/early infection.
The majority of subjects in the primary stage of HIV-1 infec-
tion have HIV-1 populations equilibrated between the blood
plasma and CSF; however, we detected compartmentalized
HIV-1 variants in the CSF populations of three primary infec-
tion subjects. Two subjects with compartmentalized variants in
the CSF were asymptomatic and did not show elevated levels
of inflammatory markers in the CSF, suggesting that compart-
mentalized virus in the CSF/CNS can occur during primary
HIV-1 infection in the absence of overt neurological symp-
toms. Additionally, sequence data from env genes obtained
from subject 9040 (165 days p.i.) suggest that HIV-1 can rap-
idly adapt to enhance viral entry and growth in the context of
the CNS environment. Early detection of CSF-compartmen-
talized variants may identify subjects that will have HIV-asso-
ciated neurological problems later during infection, since sim-
ilar compartmentalization late in infection likely indicates a
loss of control of viral replication in the periphery and is
associated with HAD (reference 26 and unpublished observa-
tion). Our results demonstrate that compartmentalization in
the CNS compartment can arise shortly after HIV-1 transmis-
sion and suggest that subjects with compartmentalization of
viral variants in the CSF during early infection should be con-
sidered for early antiretroviral therapy to reduce viral replica-
tion in the CNS.
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